Literature DB >> 23703953

Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine.

Luís Ruíz-del-Árbol1, Linette Achécar, Regina Serradilla, Miguel Á Rodríguez-Gandía, Miguel Rivero, Elena Garrido, José J Natcher.   

Abstract

UNLABELLED: We investigated left ventricular diastolic dysfunction (LVDD) and its relationship with circulatory function and prognosis in cirrhosis with portal hypertension and normal creatinine. Conventional and tissue Doppler (TDI) echocardiography, systemic and hepatic hemodynamics, and the activity of endogenous vasoactive systems (AEVS) were measured prospectively in 80 patients. Plasma renin activity (PRA; >4 ng/mL/hour) was used as a surrogate of effective arterial blood volume. Patients were followed up for 12 months. Thirty-seven patients had LVDD (19 with grade 1 and 18 with grade 2). Left ventricular hypertrophy, left atrial volume, AEVS, and natriuretic peptide levels were significantly greater in patients with LVDD than without LVDD. Patients with grade 2 LVDD, compared to grade 1 LVDD and without LVDD, had significantly lower mean arterial pressure and higher Model for End-Stage Liver Disease (MELD) score, E-wave transmitral/early diastolic mitral annular velocity (E/e' ratio), cardiopulmonary pressures, PRA, and natriuretic peptide levels. Systolic and cardiac chronotropic function were significantly lower in patients with grade 2 LVDD than without LVDD. LVDD was more frequent in patients with ascites and increased PRA than patients without ascites or with ascites but normal PRA. Fourteen patients with LVDD developed hepatorenal syndrome (HRS) type 1 on follow-up. Survival was different according to degree of LVDD (without LVDD: 95%; grade 1 LVDD: 79%; grade 2 LVDD: 39%; P < 0.001). Independent predictive factors of mortality were MELD score and E/e' ratio.
CONCLUSION: LVDD occurs simultaneously with other changes in cardiac structure and function and is associated with an impairment of effective arterial blood volume. LVDD is a sensitive marker of advanced cirrhosis, type 1 HRS development, and mortality.
© 2013 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23703953     DOI: 10.1002/hep.26509

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  38 in total

1.  Association of Cardiac Abnormalities to the Frail Phenotype in Cirrhotic Patients on the Waitlist: From the Functional Assessment in Liver Transplantation Study.

Authors:  Lorena Puchades; Stephanie Chau; John A Dodson; Yara Mohamad; Rachel Mustain; Adrienne Lebsack; Victoria Aguilera; Martin Prieto; Jennifer C Lai
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

Review 2.  Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Authors:  Suehana Rahman; Susan V Mallett
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  [Hepatocardiac disorders : Interactions between two organ systems].

Authors:  T Horvatits; A Drolz; K Rutter; K Roedl; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-06-13       Impact factor: 0.840

4.  Speckle tracking echocardiography in cirrhosis: is it ready for prime time?

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2014-01-09       Impact factor: 6.047

5.  Assessment of diastolic function in the management of patients with cirrhosis.

Authors:  Søren Møller
Journal:  Hepatol Int       Date:  2014-07-27       Impact factor: 6.047

Review 6.  Left ventricular function assessment in cirrhosis: Current methods and future directions.

Authors:  Francisco Sampaio; Joana Pimenta
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

7.  Clinical impact of pre-transplant diastolic function on outcome after allogeneic hematopoietic SCT.

Authors:  N Shingai; K Kakihana; G Oshikawa; T Kobayashi; N Doki; H Sakamaki; K Ohashi
Journal:  Bone Marrow Transplant       Date:  2014-06-16       Impact factor: 5.483

Review 8.  Recent advances in cirrhotic cardiomyopathy.

Authors:  Dimitrios S Karagiannakis; George Papatheodoridis; Jiannis Vlachogiannakos
Journal:  Dig Dis Sci       Date:  2014-11-18       Impact factor: 3.199

9.  Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis.

Authors:  Dimitrios S Karagiannakis; Jiannis Vlachogiannakos; Georgios Anastasiadis; Irini Vafiadis-Zouboulis; Spiros D Ladas
Journal:  Hepatol Int       Date:  2014-06-08       Impact factor: 6.047

Review 10.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.